摘要
目的:通过观察慈菇消脂胶囊对非酒精性脂肪性肝病(NAFLD)模型大鼠肝组织病理变化、肝功能及血脂、FFA(游离脂肪酸)的影响,探讨慈菇消脂胶囊防治该病的作用机理。方法:喂饲高脂饲料复制非酒精性脂肪肝模型,70只大鼠随机分为正常组,模型组,慈菇消脂胶囊高剂量组、中剂量组、低剂量组和吡格列酮阳性药物对照组,各组大鼠连续给药6周,观察各组大鼠肝组织病理形态学变化;检测肝功能、血脂水平和肝组织FFA含量。结果:与正常组比较,模型组肝脏病理学变化、血脂代谢、肝功能指标和肝组织FFA变化均具有统计学意义(P <0. 05);慈菇消脂胶囊各剂量组肝脏脂肪变性和炎症均有不同程度的减轻,TC、TG、LDL水平及FFA含量较模型组降低(P <0. 05),差异具有统计学意义(P <0. 05)。结论:慈菇消脂胶囊能够改善肝功能,减轻肝细胞脂肪变性,对非酒精性脂肪性肝病的治疗作用确切。
Objective: To explore the mechanism of Cigu Xiaozhi Capsule on nonalcoholic fatty liver disease( NAFLD) by observing the effects of the Capsule on pathological changes of liver tissue,hepatic function,blood lipid and FFA expression in NAFLD rats. Methods: NAFLD models were copied by giving high-fat diet,70 rats were divided into normal,model,Cigu Xiaozhi Capsule low,middle and high dose groups,each group was given the corresponding medicine for 6 weeks,the pathological changes of liver tissue were observed by optical microscope,serum ALT,AST and Blood lipid( TC,TG,HDL,LDL) levels were determined,FFA expression was determined. Results: To compare with normal group,the liver tissue pathological changes,blood lipid,ALT,AST and liver tissue FFA expression in model group were significantly changed( P < 0. 05),the hepatic steatosis and inflammation of the three dose Cigu Xiaozhi Capsule groups were alleviated at different degree,TG,TC,LDL and FFA were decreased( P < 0. 05). Conclusion: Cigu Xiaozhi Capsule can prevent NAFLD by improving hepatic function and alleviating hepatic steatosis.
引文
[1]陈瑞,高晓刚,邱磊,等.大麻二酚对大鼠非酒精性脂肪肝的治疗作用及机制[J].解放军医学杂志,2017,42(6):515-519.
[2]杨少军,孟陆亮,张立清,等.慈菇消脂丸治疗脂肪肝的临床研究[J].中国中医药科技,2009,16(5):343-344.
[3]中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南(2010年修订版)[J].现代医药卫生,2011,27(5):641-643.
[4]苏剑锋,江伟.“二次打击”对非酒精性脂肪肝的治疗作用及机制影响[J].华夏医学,2015,28(2):141-144.
[5]舒泳翔,谭诗云,吴鹏波.非酒精性脂肪肝病自噬机制研究进展[J].医学研究杂志,2016,45(1):4-7.
[6]陶森,庞树朝,郭后卉.只有中药分期论治非酒精性脂肪肝病探徽[J].上海中医药杂志,2015,49(2):61-62.
[7]季光.中医药治疗非酒精性脂肪性肝病临床试验的相关问题探讨[J].临床肝胆病杂志,2014,30(4):299-302.
[8]吕金仓,白亚军.李佃贵教授浊毒证用药经验介绍[J].新中药,2013,45(5):193-195.